A5075162981- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Adolescent and Pediatric Healthcare
- Systemic Lupus Erythematosus Research
- Kawasaki Disease and Coronary Complications
- Inflammasome and immune disorders
- Immunodeficiency and Autoimmune Disorders
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Renal Diseases and Glomerulopathies
- Chronic Lymphocytic Leukemia Research
- Streptococcal Infections and Treatments
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Sarcoidosis and Beryllium Toxicity Research
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Salivary Gland Disorders and Functions
- Vasculitis and related conditions
- Ocular Diseases and Behçet’s Syndrome
- Peripheral Neuropathies and Disorders
- Pregnancy and Medication Impact
- Eosinophilic Disorders and Syndromes
- Eosinophilic Esophagitis
- Salivary Gland Tumors Diagnosis and Treatment
Kagoshima University
2014-2025
Kagoshima University Hospital
2011-2023
RMIT University
2008-2017
Kagoshima City Hospital
1998-2017
Boston Children's Hospital
2014
Center for Children
2011
Japanese Urological Association
2003
Children's Hospital of Los Angeles
2001
University of Southern California
2001
Kyushu Hospital
1998
To investigate the efficacy and safety of interleukin-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK).Patients TAK who had relapsed within previous 12 weeks were induced into remission oral glucocorticoid therapy. In this double-blind, placebo-controlled trial, randomly assigned 1:1 to receive weekly 162 mg or placebo subcutaneously, glucocorticoids tapered 10 %/week from week 4 a minimum 0.1 mg/kg/day until 19 relapsed. The primary endpoint was time relapse TAK,...
To evaluate the safety and efficacy of tumor necrosis factor fusion protein etanercept in children with treatment-resistant uveitis.Ten chronic active uveitis (7 girls 3 boys, mean age 7.5 years [range 3-12 years]) were enrolled this prospective study. In 7 children, was associated pauciarticular juvenile rheumatoid arthritis. Five antinuclear antibody positive. All patients had failed previous therapy topical steroids methotrexate and/or cyclosporine. treated at a dosage 0.4 mg/kg twice...
Objective. An all-patient postmarketing surveillance program was conducted to evaluate the safety and effectiveness of tocilizumab (TCZ) for rheumatoid arthritis (RA) in real-world clinical setting Japan. Methods. Patients received 8 mg/kg TCZ every 4 weeks were observed 28 weeks. Data collected on patient characteristics, drug effectiveness. Results. A total 7901 patients enrolled. Percentages serious adverse events (AE) 43.9% 9.6%, respectively. The most common AE infections (3.8%)....
An interim analysis of an all-patient postmarketing surveillance programme in Japan to investigate the safety tocilizumab for treatment rheumatoid arthritis (RA) real world.This included 3881 patients. Patients received 8 mg/kg every 4 weeks, and were observed 28 weeks. Data on baseline characteristics adverse events (AE) collected.Total serious AE reported as 167 27 events/100 patient-years, respectively. The most frequent infections. Logistic regression identified following risk factors...
Objectives. To confirm the safety and effectiveness of adalimumab to evaluate influence concomitant use methotrexate (MTX). Methods. Postmarketing surveillance 7740 Japanese rheumatoid arthritis (RA) patients was performed. All who received in registration period were followed for 28 weeks after starting treatment 24 effectiveness. Effectiveness measured by duration morning stiffness, swollen tender joint counts (28 joints), patient global assessment disease activity, erythrocyte...
Objective To compare the capacity of 2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis (HLH‐2004) with preliminary systemic juvenile idiopathic arthritis (JIA)–associated macrophage activation syndrome (MAS) to discriminate MAS complicating JIA from 2 potentially confusable conditions, represented by active without and infection. Methods International pediatric rheumatologists hemato‐oncologists were asked retrospectively collect clinical information patients JIA–associated...
: Familial cold autoinflammatory syndrome, Muckle-Wells syndrome (MWS), and chronic, infantile, neurological, cutaneous articular (CINCA) are dominantly inherited diseases associated to gain-of-function NLRP3 mutations included in the cryopyrin-associated periodic syndromes (CAPS). A variable degree of somatic mosaicism has been detected ≈35% patients with CINCA. However, no data currently available regarding relevance this mechanism other CAPS phenotypes.To evaluate as disease-causing...
To investigate the long-term efficacy and safety of IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK).Patients completing randomized, double-blind, placebo-controlled period TAKT (Takayasu Treated Tocilizumab) trial were followed up during open-label extended treatment weekly s.c. 162 mg for to 96 weeks or longer, oral glucocorticoid tapering performed at investigators' discretion. Endpoints extension analysis included steroid-sparing effects tocilizumab, imaging...
In 2018, intravenous abatacept was approved for the treatment of refractory polyarticular-course juvenile idiopathic arthritis (JIA) in Japan. However, reports describing effectiveness and safety clinical practice Japanese patients with JIA are limited. Therefore, this postmarketing surveillance study aimed to evaluate real-world pediatric JIA. This evaluated included an all-case between February 2018 August 2020 who were treated abatacept. Data on registered collected during 52-week...
To investigate the prevalence of cumulative organ damage in patients with juvenile-onset systemic lupus erythematosus (SLE) and its association demographic clinical variables, medication use, quality life.The occurrence system damage, as measured by Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index (SDI), was determined for 387 consecutively enrolled pediatric rheumatology centers from Europe, US, Mexico, Japan. Risk factors included variables;...
Objective: To perform a postmarketing surveillance study evaluating the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis (RA). Methods: Safety data were collected for all RA (at 772 sites) treated intravenous between September 2010 June 2011. Patients by approved dosing regimen according to package insert. Treatment was evaluated at baseline weeks 4, 12, 24 using Disease Activity Score 28 (DAS28) erythrocyte sedimentation rate or serum C-reactive protein...
Objective. To assess the longterm safety and effectiveness of tocilizumab (TCZ) in systemic-onset juvenile idiopathic arthritis (sJIA). Methods. The extension phase 2 pivotal studies (phase II with 11 patients III 56 patients) active sJIA was analyzed. Patients received open-label TCZ (8 mg/kg, every weeks) without concomitant use disease-modifying antirheumatic drugs. Results. In total, 67 were enrolled. All corticosteroid at baseline. Median duration exposure to 3.4 years. Nine withdrew...
Objectives To collect clinical information and NOD2 mutation data on patients with Blau syndrome to evaluate their prognosis. Methods Fifty mutations were analysed. The activity of each mutant was evaluated in HEK293 cells by reporter assay. Clinical collected from medical records through the attending physicians. Results study population comprised 26 males 24 females aged 0–61 years. Thirty-two cases sporadic, 18 familial 9 unrelated families. Fifteen different identified, including 2 novel...
Abstract Objective To assess the health‐related quality of life (HRQL) patients with juvenile‐onset systemic lupus erythematosus (JSLE) and its relationship disease activity accumulated damage. Methods In this cross‐sectional study, HRQL was assessed using Child Health Questionnaire (CHQ), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), damage International Collaborating Clinics/American College Rheumatology Damage (SDI). Results A total 297 were included. The mean ± SD...
Journal Article Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis Get access Tomoyuki Imagawa, Imagawa Department Pediatrics, Yokohama City University School Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan Correspondence to: e-mail: timagawa@med.yokohama-cu.ac.jp Search for other works by this author on: Oxford Academic Google Scholar Shumpei Yokota, Yokota Masaaki Mori,...
The objective of this study was to evaluate the efficacy, pharmacokinetics, and safety adalimumab in patients with polyarticular juvenile idiopathic arthritis (JIA) Japan. Patients aged 4 17 years were enrolled a single-arm, open-label, multicentre adalimumab. weighing <30 kg received 20 mg every other week (eow), those ≥30 40 eow. Concomitant methotrexate (MTX) allowed (≤10 mg/m(2) per week). primary efficacy outcome percent American College Rheumatology Pediatric 30 response (ACR Pedi 30)...
Abstract The aberrant induction of proinflammatory cytokines is considered to be crucial in the pathogenesis systemic juvenile idiopathic arthritis and adult‐onset Still's disease. Interleukin‐18 (IL‐18) particular has been reported a candidate for key cytokine both diseases; however, origin IL‐18 unclear. To clarify origin, we investigated specimens from various organs obtained during autopsy child with JIA macrophage activation syndrome, using immunohistochemical staining. Our results...
We evaluated the safety and efficacy of tocilizumab in polyarticular-course juvenile idiopathic arthritis (pJIA) with polyarticular or oligoarticular onset. Patients received 8 mg/kg every 4 weeks open-label studies: initial study (to week 12) then an extension (at least 48 weeks). Nineteen patients intractable to conventional methotrexate therapy were enrolled. Seventeen had polyarticular-onset pJIA; two oligoarticular-onset pJIA. Mean age was 11.6 years; mean disease duration 5.3 years....